Filtered By:
Therapy: Antiviral Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 43 results found since Jan 2013.

Immediately early 2 (IE-2) and DNA polymerase SiRNA as virus-specific antiviral against novel transplacental cytomegalovirus strain ALL-03 in vitro
CONCLUSION: In conclusion, this study clearly highlighted the feasibility of RNAi as an alternative antiviral therapy that could lead to controlling the CMV infection.PMID:33640483 | DOI:10.1016/j.meegid.2021.104783
Source: Infection, Genetics and Evolution - February 28, 2021 Category: Genetics & Stem Cells Authors: Krishnan Nair Balakrishnan Ashwaq Ahmed Abdullah Jamilu Abubakar Bala Faez Firdaus Abdullah Jesse Che Azurahanim Che Abdullah Mustapha Mohamed Noordin Mohd Lila Mohd-Azmi Source Type: research

Kinome siRNA screen identifies novel cell-type specific dengue host target genes
Publication date: October 2014 Source:Antiviral Research, Volume 110 Author(s): Yong-Jun Kwon , Jinyeong Heo , Hazel E.E. Wong , Deu John M. Cruz , Sumathy Velumani , Camila T. da Silva , Ana Luiza P. Mosimann , Claudia N. Duarte dos Santos , Lucio H. Freitas-Junior , Katja Fink Dengue is a global emerging infectious disease, with no specific treatment available. To identify novel human host cell targets important for dengue virus infection and replication, an image-based high-throughput siRNA assay screening of a human kinome siRNA library was conducted using human hepatocyte cell line Huh7 infected with a recent dengue...
Source: Antiviral Therapy - November 13, 2014 Category: Infectious Diseases Source Type: research

Expression of a single siRNA against a conserved region of NP gene strongly inhibits in vitro replication of different Influenza A virus strains of avian and swine origin
In conclusion, these findings reveal new siRNA sequences able to inhibit Influenza A virus replication and provide a basis for the development of siRNAs as prophylaxis and therapy for influenza infection both in humans and animals.
Source: Antiviral Therapy - May 17, 2015 Category: Virology Source Type: research

Susceptibility of Enterovirus-D68 to RNAi-mediated antiviral knockdown
Publication date: Available online 20 July 2019Source: Antiviral ResearchAuthor(s): Nicholas Klaiber, Michael A. McVoy, Wei ZhaoAbstractEnterovirus D68 (EV-D68) represents an emerging pathogen which has demonstrated a capacity for causing epidemic illness in pediatric and immunocompromised patients. With no effective antiviral treatment available, therapeutic interventions are currently limited to supportive care. Utilizing available genomic sequences from the 2014 B3 Epidemic EV-D68 clade and the 1962 Fermon EV-D68 strains, we performed in silico comparative genomic analysis, identifying several islands of phylogenetic co...
Source: Antiviral Therapy - July 21, 2019 Category: Virology Source Type: research

Inhibition of influenza A virus by mixed siRNAs, targeting the PA, NP, and NS genes, delivered by hybrid microcarriers
In conclusion, we have developed a proof-of-principle which shows that our hybrid microcarrier technology (utilizing a therapeutic siRNA cocktail) may represent a promising approach in anti-influenza therapy.Graphical abstract
Source: Antiviral Therapy - August 6, 2018 Category: Virology Source Type: research

Inhibition of hepatitis B virus (HBV) gene expression and replication by HBx gene silencing in a hydrodynamic injection mouse model with a new clone of HBV genotype B
Conclusions: Taken together, the HI mouse model with a HBV genotype B genome was successfully established and showed different characteristics in vivo compared with the genotype A genome. The effectiveness of gene silencing against HBx gene determines whether HBV replication may be sustainably inhibited by siRNA in vivo.
Source: Virology Journal - June 28, 2013 Category: Virology Authors: Lei LiHong ShenAnyi LiZhenhua ZhangBaoju WangJunzhong WangXin ZhengJun WuDongliang YangMengji LuJingjiao Song Source Type: research

Enhanced suppression of adenovirus replication by triple combination of anti-adenoviral siRNAs, soluble adenovirus receptor trap sCAR-Fc and cidofovir
Publication date: August 2015 Source:Antiviral Research, Volume 120 Author(s): Tanja Pozzuto , Carsten Röger , Jens Kurreck , Henry Fechner Adenoviruses (Ad) generally induce mild self-limiting respiratory or intestinal infections but can also cause serious disease with fatal outcomes in immunosuppressed patients. Antiviral drug therapy is an important treatment for adenoviral infections but its efficiency is limited. Recently, we have shown that gene silencing by RNA interference (RNAi) is a promising new approach to inhibit adenoviral infection. In the present in vitro study, we examined whether the efficiency of an R...
Source: Antiviral Therapy - June 2, 2015 Category: Virology Source Type: research

Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs
Despite significant efforts, there are currently no approved treatments for COVID-19. However, biotechnological approaches appear to be promising in the treatment of the disease. Accordingly, nucleic acid-based treatments including aptamers and siRNAs are candidates that might be effective in COVID-19 treatment. Aptamers can hamper entry and replication stages of the SARS-CoV-2 infection, while siRNAs can cleave the viral genomic and subgenomic RNAs to inhibit the viral life cycle and reduce viral loads. As a conjugated molecule, aptamer–siRNA chimeras have proven to be dual-functioning antiviral therapy, acting both as ...
Source: Frontiers in Microbiology - November 8, 2021 Category: Microbiology Source Type: research

Inhibition of adenovirus multiplication by short interfering RNAs directly or indirectly targeting the viral DNA replication machinery
Publication date: June 2012 Source:Antiviral Research, Volume 94, Issue 3 Author(s): Doris Kneidinger , Mirza Ibrišimović , Thomas Lion , Reinhard Klein Human adenoviruses are a common threat to immunocompromised patients, e.g., HIV-positive individuals or solid-organ and, in particular, allogeneic stem cell transplant recipients. Antiviral drugs have a limited effect on adenoviruses, and existing treatment modalities often fail to prevent fatal outcome. Silencing of viral genes by short interfering RNAs (siRNAs) holds a great promise in the treatment of viral infections. The aim of the present study was to identify ad...
Source: Antiviral Therapy - November 16, 2014 Category: Virology Source Type: research

Small interfering RNAs targeting peste des petits ruminants virus M mRNA increase virus-mediated fusogenicity and inhibit viral replication in vitro
In this study, three different small interfering RNAs (siRNA) were designed on the basis of translated region for PPRV Nigeria 75/1 M mRNA, and were subsequently synthesized for their transfection into Vero-SLAM cells, followed by infection with PPRVs. The results showed that two out of three siRNAs robustly induced cell-to-cell fusion as early as 36 hours post-infection with PPRVs, effectively suppressed expression of the M protein by interference for the M mRNA, and eventually inhibited viral replication in vitro. These findings led us to speculate that siRNA-mediated knockdown of the M protein would alter its interactio...
Source: Antiviral Therapy - August 26, 2015 Category: Virology Source Type: research

Interleukin-24 inhibits influenza A virus replication in vitro through induction of toll-like receptor 3 dependent apoptosis
This study demonstrates that IL-24 reduces the titer of different influenza A virus subtypes independently of type I interferon in an apoptosis dependent manner. The anti-viral effect of IL-24 correlated with caspase-3 activation and could be blocked by a pan-caspase inhibitor and by small interfering RNA (siRNA) directed towards TLR3. Surprisingly, caspase-3 activation in influenza A virus/IL-24-stimulated cells correlated with the down-regulation of the B-cell lymphoma 2 (Bcl-2) family member myeloid cell leukemia 1 (Mcl-1). Correspondingly, knockdown of Mcl-1 by siRNA enhanced caspase activation in influenza A virus inf...
Source: Antiviral Therapy - September 14, 2015 Category: Virology Source Type: research

In vitro inhibition of African swine fever virus-topoisomerase II disrupts viral replication
Publication date: Available online 26 August 2016 Source:Antiviral Research Author(s): Ferdinando B. Freitas, Gonçalo Frouco, Carlos Martins, Alexandre Leitão, Fernando Ferreira African swine fever virus (ASFV) is the etiological agent of a highly-contagious and fatal disease of domestic pigs, leading to serious socio-economic impact in affected countries. To date, neither a vaccine nor a selective anti-viral drug are available for prevention or treatment of African swine fever (ASF), emphasizing the need for more detailed studies at the role of ASFV proteins involved in viral DNA replication and transcription. Notably,...
Source: Antiviral Therapy - August 25, 2016 Category: Virology Source Type: research

In  vitro inhibition of African swine fever virus-topoisomerase II disrupts viral replication
Publication date: October 2016 Source:Antiviral Research, Volume 134 Author(s): Ferdinando B. Freitas, Gonçalo Frouco, Carlos Martins, Alexandre Leitão, Fernando Ferreira African swine fever virus (ASFV) is the etiological agent of a highly-contagious and fatal disease of domestic pigs, leading to serious socio-economic impact in affected countries. To date, neither a vaccine nor a selective anti-viral drug are available for prevention or treatment of African swine fever (ASF), emphasizing the need for more detailed studies at the role of ASFV proteins involved in viral DNA replication and transcription. Notably, ASFV e...
Source: Antiviral Therapy - September 1, 2016 Category: Virology Source Type: research

Caffeic acid inhibits HCV replication via induction of IFN α antiviral response through p62-mediated Keap1/Nrf2 signaling pathway
In this study, we showed that CA could notably inhibit HCV replication. Mechanism study demonstrated that CA could induce HO-1 expression, which would trigger the IFNα antiviral response, and the antiviral effect of CA was attenuated when HO-1 activity was inhibited by SnPP (an HO-1 inhibitor). CA could also increase erythroid 2-related factor 2 (Nrf2) expression. When Nrf2 was knocked down by specific siRNA, HO-1 expression was concomitantly decreased while HCV expression was restored. Further study indicated that kelch-like ECH-associated protein 1 (Keap1) expression was decreased by CA in a p62/Sequestosome1 (p62)-depe...
Source: Antiviral Therapy - April 14, 2018 Category: Virology Source Type: research